El­e­va­tion On­col­o­gy dips its toes in­to AD­Cs, adding sec­ond drug to its bag. But is it pit­ting it­self against Bris­tol My­ers?

As in­ter­est grows in an­ti­body drug con­ju­gates, an­oth­er small play­er is jump­ing in­to the space with sights set on an in­creas­ing­ly pop­u­lar tar­get.

On Wednes­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER